Search

Your search keyword '"Chan, H. L.‐Y."' showing total 389 results
Start Over Author "Chan, H. L.‐Y."
389 results on '"Chan, H. L.‐Y."'

64. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

Author

Chan, H. L. Y. Messinger, D. Papatheodoridis, G. V. and Cornberg, M. Xie, Q. Piratvisuth, T. Ren, H. Kennedy, P. T. Thompson, A. Caputo, A. Bakalos, G. Pavlovic, V. and Lampertico, P.

Subjects
virus diseases, digestive system diseases
Abstract

Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or >= 5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA >= 2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or 5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg >= 20000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg >= 20000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value=97% [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

Published
2018

66. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm

Author

Chan, H. L. Y., Chen, C. J., Omede, O., Al Qamish, J., Al Naamani, K., Bane, A., Tan, S. S., Simonova, M., Cardenas, I., Derbala, M., Akin, O., Phillips, R. O., Abdelmageed, M. K., Abdulla, M., Adda, D., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Sadadi, M., Al Salman, J., AlBadri, M., Al-Busafi, S. A., Al-Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mateva, L., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Mustapha, B., Nersesov, A., Ngige, E., Njouom, R., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omuemu, C., Ondoa, P., Opare- Sem, O., Owusu-Ofori, S., Prokopenko, Y. N., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Su, T. H., Sultan, K., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Nde, H.

Subjects
parasitic diseases, hepatitis C, incidence, mortality, prevalence, treatment, geographic locations
Abstract

Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman) ; however, HCV-related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high-treatment rate will contribute to a reduction in total cases and HCV- related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV- related morbidity and mortality.

Published
2017

67. Strategies to manage hepatitis C virus infection disease burden

Author

Chen, D. S., Hamoudi, W., Mustapha, B., Layden, J., Nersesov, A., Reic, T., Garcia, V., Rios, C., Mateva, L., Njoya, O., Al-Busafi, S. A., Abdelmageed, M. K., Abdulla, M., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al-Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Nde, H., Ngige, E., Njouom, R., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Opare-Sem, O., Owusu-Ofori, S., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Redae, B., Rinke de Wit, T., Robbins, S., Roberts, L. R., Sanad, S. J., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Schmelzer, J. D.

Subjects
diagnosis, disease burden, elimination, epidemiology, hepatitis C, scenarios, strategy
Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets —“WHO Targets” (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.

Published
2017

68. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

Author

Chan, H. L. Y., primary, Messinger, D., additional, Papatheodoridis, G. V., additional, Cornberg, M., additional, Xie, Q., additional, Piratvisuth, T., additional, Ren, H., additional, Kennedy, P. T., additional, Thompson, A., additional, Caputo, A., additional, Bakalos, G., additional, Pavlovic, V., additional, and Lampertico, P., additional

Published
2018
Full Text
View/download PDF

69. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

Author

Chuang, W.-L., primary, Jia, J., additional, Chan, H. L. Y., additional, Han, K.-H., additional, Tanwandee, T., additional, Tan, D., additional, Chen, X., additional, Gane, E., additional, Piratvisuth, T., additional, Chen, L., additional, Xie, Q., additional, Sung, J. J.-Y., additional, Messinger, D., additional, Wat, C., additional, Bakalos, G., additional, and Liaw, Y. F., additional

Published
2018
Full Text
View/download PDF

72. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B

Author

Marcellin, P. Ahn, S. H. Chuang, W. -L. Hui, A. J. and Tabak, F. Mehta, R. Petersen, J. Lee, C. -M. Ma, X. and Caruntu, F. A. Tak, W. Y. Elkhashab, M. Lin, L. Wu, G. and Martins, E. B. Charuworn, P. Yee, L. J. Lim, S. G. and Foster, G. R. Fung, S. Morano, L. Samuel, D. Agarwal, K. and Idilman, R. Strasser, S. I. Buti, M. Gaeta, G. B. and Papatheodoridis, G. Flisiak, R. Chan, H. L. Y.

Abstract

Background In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy. Aim To identify baseline and on-treatment factors associated with HBsAg loss at Week 72 and provide a model for predicting HBsAg loss in patients receiving combination therapy for 48 weeks. Methods A secondary analysis of data from an open-label study where patients were randomised to TDF (300 mg/day, oral) plus PEG-IFN (PI, 180 mu g/week, subcutaneous) for 48 weeks (TDF/PI-48w); TDF plus PEG-IFN for 16 weeks, TDF for 32 weeks (TDF/PI-16w+TDF-32w); TDF for 120 weeks (TDF-120w) or PEG-IFN for 48 weeks (PI-48w). Logistic regression methods were used to identify models that best predicted HBsAg loss at Week 72. Results Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09). The only baseline factor associated with response was genotype A. HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001). HBsAg decline >3.5 log(10) IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72. Conclusions HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.

Published
2016

77. Higher hepatitis B surface antigen loss among whites compared to asians after stopping nucleos(t)ide analogue therapy in a large, global, multiethnic cohort of patients with chronic hepatitis B.

Author

Hirode, G., Hansen, B. E., Chen, C.-H., Su, T.-H., Seto, W.-K., Wong, G., Van Hees, S., Papatheodoridi, M., Lens, S., Brakenhoff, S. M., Choi, H. S. J., Chien, R.-N., Feld, J. J., Sonneveld, M., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Chan, H. L. Y., Yuen, M.-F., and Kao, J.-H.

Published
2021

78. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B

Author

Marcellin, P., primary, Ahn, S. H., additional, Chuang, W.-L., additional, Hui, A. J., additional, Tabak, F., additional, Mehta, R., additional, Petersen, J., additional, Lee, C.-M., additional, Ma, X., additional, Caruntu, F. A., additional, Tak, W. Y., additional, Elkhashab, M., additional, Lin, L., additional, Wu, G., additional, Martins, E. B, additional, Charuworn, P., additional, Yee, L. J., additional, Lim, S. G., additional, Foster, G. R., additional, Fung, S., additional, Morano, L., additional, Samuel, D., additional, Agarwal, K., additional, Idilman, R., additional, Strasser, S. I., additional, Buti, M., additional, Gaeta, G. B., additional, Papatheodoridis, G., additional, Flisiak, R., additional, and Chan, H. L. Y., additional

Published
2016
Full Text
View/download PDF

81. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Author

Sarin, S. K., primary, Kumar, M., additional, Lau, G. K., additional, Abbas, Z., additional, Chan, H. L. Y., additional, Chen, C. J., additional, Chen, D. S., additional, Chen, H. L., additional, Chen, P. J., additional, Chien, R. N., additional, Dokmeci, A. K., additional, Gane, Ed, additional, Hou, J. L., additional, Jafri, W., additional, Jia, J., additional, Kim, J. H., additional, Lai, C. L., additional, Lee, H. C., additional, Lim, S. G., additional, Liu, C. J., additional, Locarnini, S., additional, Al Mahtab, M., additional, Mohamed, R., additional, Omata, M., additional, Park, J., additional, Piratvisuth, T., additional, Sharma, B. C., additional, Sollano, J., additional, Wang, F. S., additional, Wei, L., additional, Yuen, M. F., additional, Zheng, S. S., additional, and Kao, J. H., additional

Published
2015
Full Text
View/download PDF

100. The rt A181 S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.

Author

Liu, Y., Li, X., Xin, S., Xu, Z., Chen, R., Yang, J., Liu, L., Wong, V. W.‐S., Yang, D., Chan, H. L.‐Y., and Xu, D.

Subjects
HEPATITIS B, GENETIC mutation, HEPATITIS B virus, ADEFOVIR dipivoxil, DRUG resistance, REVERSE transcriptase, PATIENTS
Abstract

The study aimed to clarify clinical significance of hepatitis B virus ( HBV) rtA181S mutation in Chinese HBV-infected patients. A total of 18 419 patients with chronic HBV infection from Beijing 302 Hospital were investigated. HBV complete reverse transcriptase region of polymerase was screened by direct sequencing, and the results were verified by clonal sequencing. Replication-competent mutant and wild-type HBV genomic amplicons were constructed and transfected into the HepG2 cells and cultured in the presence or absence of serially diluted nucleos(t)ide analogues. Intracellular HBV replicative intermediates were quantitated for calculating the 50% effective concentration of the drug ( EC50). The rtA181S was detected in 98 patients with 12 kinds of mutational patterns. Genotype C and genotype B HBV infection occupied 91.8% and 8.2% in rtA181S-positive patients, in contrast to 84.6% and 15.4% in rtA181S-negative patients ( P < 0.01). All rtA181S-positive patients had received nucleos(t)ide analogues. rtA181S was detected in multiple patients with virologic breakthrough. Phenotypic analysis of patient-derived viral strains showed that rtA181S, rtA181S+N236T, rtN236T and rtA181V strains had 68.5%, 49.9%, 71.4% and 66.2% of natural replication capacity of wild-type strain, and 3.7-fold, 9.8-fold, 7.9-fold and 5.6-fold increased EC50 to adefovir dipivoxil ( ADV). The rtA181S strain remained susceptible to lamivudine, entecavir and tenofovir, and ADV susceptibility was restored after the mutation was eliminated through site-directed mutagenesis. Rescue therapy with entecavir or combination therapy was effective in rtA181S-related ADV-refractory patients. The rtA181S mutation confers moderate resistance to ADV. It could be induced by either lamivudine or ADV and contribute ADV treatment failure. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results